Highlights•Solid cancers are molecular complex and heterogeneous diseases.•Genomic
complexity and heterogeneity are the main culprits for the limited response to selective …

Multi-target therapies, either in combination or in sequential order, have been advocated to
combat intrinsic and acquired resistance to anti-cancer drugs (Holohan et al., 2013; Yardley …

The rapidly expanding knowledge of the pathogenesis of cancer at the molecular level is
providing new targets for drug discovery and development. However, cancer is a complex …

Cancer is a major public health problem worldwide with more than an estimated 19.3 million
new cases in 2020. The occurrence rises dramatically with age, and the overall risk …

Future Med. Chem.(2012) 4 (4) 388 future science group and metastasis and integrate
information such as mutational ana lysis, copy number, geneexpression changes, metabolic …

Although the vast majority of diseases are multi-factorial in nature, most modern drug
discovery is based on identifying a drug that acts on a single derangement felt to be involved …

A new strategy for cancer therapy has emerged during the past decade based on molecular
targets that are less likely to be essential in all cells in the body, therefore confer a wider …

Despite enormous progress in the treatment of many malignancies, the development of
cancer resistance is still an important reason for cancer chemotherapy failure. Increasing …

Simple Summary Today, a significant issue in treating the most common cancers is their
resistance to current treatment options like chemotherapy, radiotherapy, or immunotherapy …

Whether it is chronic myeloid leukemia, ALK-expressing malignancies, or HER2-positive
breast cancer, targeted-therapies for treatment of human cancers have shown great …